Xencor (XNCR) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.29
- Estimate
- -$0.76
- Surprise
- +62.0%
- Revenue (period 2026-06-30)
- $51.2M
- Score today
- 5.1/10
Revenue source: xbrl.
How the report landed
Xencor (XNCR) reported a narrower loss than forecast — adjusted EPS of -$0.29 against the -$0.76 estimate (a 62.0% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates XNCR Sell at 5.1/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +62.0% surprise compares with a +27.2% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Geographic: California
- Quality below floor (2.3 < 4.0)
- Reward/Risk 1.1:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.16
- Price target
- $32.63
- Stop
- $26.19
- Upside to target
- +15.9%
- Reward-to-risk
- 1.1:1
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
XNCR at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.17B
- P/E (fwd)
- -8.2
- 52-week range
- $10.38–$33.60
- Off 52-week high
- 16.2%
- RSI (14)
- 65
- Volume vs avg
- 0.17×
- Score today
- 5.1/10